KENACORT ® Triamcinolone acetonide

KENACORT ® is a drug based on Triamcinolone acetonide

THERAPEUTIC GROUP: Unassociated systemic corticosteroids

Indications KENACORT ® Triamcinolone acetonide

KENACORT ® is used, in the form of intramuscular injections, in the treatment of both inflammatory and allergic morbid conditions for which the administration of steroid drugs is required.
Furthermore, the possibility of resorting to intra-articular and intra-borsal injections makes it possible to optimally manage joint and tendon inflammatory pathologies.

Mechanism of action KENACORT ® Triamcinolone acetonide

The triamcinolone acetonide contained in KENACORT ® is a systemic corticosteroid which in this formulation lends itself to the exclusive use intramuscularly and intraarticularly, guaranteeing a significantly longer duration of action than that of corticosteroids taken orally.
However, like these, it acts with the same mechanism of action, ie by inducing the expression of the enzyme lipocortin, capable of inhibiting phospholipase A2 and consequently reducing the availability of arachidonic acid.
The reduced concentration of the starting substrate results in a modest synthesis of inflammatory mediators such as leukotrienes, prostaglandins and prostacyclines with a consequent control of the entire inflammatory process and the related tissue damage.
Once its activity is terminated, the active principle is metabolized in the liver, mainly by hydroxylation processes and subsequently excreted via the kidneys.

Studies carried out and clinical efficacy

1. KENACORT AND CATARACT

Ocul Immunol Inflamm. 2010 Oct; 18: 402-7.

Intraoperative intravitreal injection of triamcinolone acetonide for cataract extraction in patients with uveitis.

Alkawas AA, Hamdy AM, Shahien EA.

Intravitreal administration of triamcinolone has been shown to be particularly effective in controlling postoperative inflammation after cataract extraction in patients suffering from uveitis, thus sparing the use of systemic steroids and related side effects.

2. TRIAMCINOLONE AND POST-OPERATIVE PAIN

Eur Spine J. 2010 Jul; 19: 1099-103.

Efficacy of triamcinolone acetonide and bupivacaine for pain after lumbar discectomy.

Bahari S, El-Dahab M, Cleary M, Sparkes J.

The administration of triamcinolone acetonide has been shown to be useful in reducing post-operative pain and the relative need for opioids following lumbar dissectomy, also significantly reducing hospitalization times.

3. TRIAMCINOLONE AND DERMATOLOGICAL PATHOLOGIES

J Drugs Dermatol. 2009 Jun; 8: 580-5.

Intramuscular triamcinolone: ​​a safe, effective and underutilized dermatologic therapy.

Robins DN.

From numerous clinical evidences it emerges that the intramuscular administration of triamcinolone acetonide should be considered primary therapy for many chronic dermatological diseases, which require a systemic approach, given the good tolerability and very high efficacy.

Method of use and dosage

KENACORT ® suspension for injection, vials of 40 mg triamcinolone acetonide per ml: the dosage to be used and the route of administration vary from patient to patient, adapting to therapeutic and clinical needs.
The difficulty in choosing the dosage and the complex maneuver of inoculation, whether it is systemic (intramuscular) or local (intraarticular), require medical supervision throughout the treatment period.

KENACORT ® Triamcinolone acetonide warnings

The particular formulation of KENACORT ® requires medical supervision throughout the treatment, both for the possible dosage correction and for the complex method of administration.
The prolonged action of triamcinolone is evidently suited to the treatment of chronic inflammatory pathologies, while it is not recommended in acute ones.
The anti-inflammatory action of these active ingredients could reduce the preventive efficacy of immunizing strategies and at the same time lower immune surveillance, increasing the risk of reactivation of latent infectious diseases or new infections.
Particular attention should be paid to patients suffering from hepatic, renal, cardiovascular, gastrointestinal, neurological, psychiatric and diabetes diseases given the ability of these drugs to worsen the clinical manifestations.
It is recommended not to administer the drug under the age of 6 and to be assisted by healthcare personnel during the inoculation of KENACORT ®
Furthermore, the presence of nervous manifestations could make it dangerous to carry out activities that require an intellectual commitment.

PREGNANCY AND BREASTFEEDING

Several experimental studies conducted on laboratory mice show how corticosteroids can easily cross the blood-placental barrier causing serious repercussions on the health of the fetus.
These evidences and the absence of clinical trials able to clarify the safety profile of triamcinolone when taken during pregnancy, advise against the use of these drugs during the entire pregnancy period and the subsequent lactation period.
The administration could be justified only in case of real need and under strict medical supervision, taking care to monitor the adrenal function of the newborn in order to exclude any hypoadrenalism.

Interactions

The efficacy of corticosteroid therapy can be seriously compromised by the concomitant intake of other active ingredients, capable of varying the pharmacokinetic characteristics and biological efficacy of Triamcinolone acetonide.
Studies in this regard have been conducted on amphotericin B, anticholinesterases, cicolisporin, digitalis glycosides, estrogens, hepatic enzyme inducers, ketoconazole, muscle relaxants and NSAIDs, with worrying results regarding the significant pharmacokinetic variations observed both for the drug in question and for the aforementioned principles. active.

Contraindications KENACORT ® Triamcinolone acetonide

The use of KENACORT ® is contraindicated in the course of systemic infections, idiopathic purpura thrombocytopenia, in pediatric patients and in case of hypersensitivity to the active substance or to one of its excipients.

Undesirable Effects - Side Effects

The use of KENACORT ® exposes the patient to the same risks as any anti-inflammatory therapy based on cortisone drugs.
A series of local reactions are added to the complex symptomatological picture determined by the systemic effects of corticosteroids, characterized by redness, pain, hypopigmentation, atrophy and sterile abscesses, linked to the particular route of administration of the drug.
Like any other cortisone therapy, the intake of KENACORT ® especially if continued for prolonged times or carried out at high doses could cause alterations in the load:
- of the musculoskeletal system with an increased risk of osteoporosis, fractures and myopathies;
- of the nervous system with neurological and psychiatric manifestations;
- of the gastrointestinal tract subjected to lack of protection of the mucosa, therefore to an increased risk of ulcers;
- of the endocrine-metabolic structure with alterations of the hypothalamus-pituitary axis, negativization of the nitrogen balance and alterations of glucose metabolism;
- electrolyte balance, with sodium retention and hypertension potentially dangerous for cardiovascular function.

Note

KENACORT ® can only be sold under medical prescription.
The use of KENACORT ® without therapeutic necessity during sports competitions constitutes doping.

The information on KENACORT ® Triamcinolone acetonide published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.